Department of Psychosis Studies, King's College London, London, UK.
Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland.
J Psychopharmacol. 2021 Jul;35(7):814-822. doi: 10.1177/02698811211001107. Epub 2021 Apr 16.
Emerging evidence supports the antipsychotic effect of cannabidiol, a non-intoxicating component of cannabis, in people with psychosis. Preclinical findings suggest that this antipsychotic effect may be related to cannabidiol modulating glutamatergic signalling in the brain.
The purpose of this study was to investigate the effects of cannabidiol on the neurochemical mechanisms underlying psychosis.
We investigated the effects of a single oral dose of cannabidiol (600 mg) in patients with psychosis, using a double-blind, randomised, placebo-controlled, repeated-measures, within-subject cross-over design. After drug administration, 13 patients were scanned using proton magnetic resonance spectroscopy to measure left hippocampal glutamate levels. Symptom severity was rated using the Positive and Negative Syndrome Scale 60 min before drug administration (pre-scan), and 270 min after drug administration (post-scan). Effects of cannabidiol on hippocampal glutamate levels, symptom severity, and correlations between hippocampal glutamate and symptoms were investigated.
Compared to placebo, there was a significant increase in hippocampal glutamate (=0.035), and a significantly greater decrease in symptom severity (=0.032) in the psychosis patients under cannabidiol treatment. There was also a significant negative relationship between post-treatment total Positive and Negative Syndrome Scale score and hippocampal glutamate (=0.047), when baseline Positive and Negative Syndrome Scale score, treatment (cannabidiol vs placebo), and interaction between treatment and glutamate levels were controlled for.
These findings may suggest a link between the increase in glutamate levels and concomitant decrease in symptom severity under cannabidiol treatment observed in psychosis patients. Furthermore, the findings provide novel insight into the potential neurochemical mechanisms underlying the antipsychotic effects of cannabidiol.
越来越多的证据支持大麻的非成瘾成分大麻二酚(CBD)在精神病患者中的抗精神病作用。临床前研究结果表明,这种抗精神病作用可能与 CBD 调节大脑中的谷氨酸能信号有关。
本研究旨在探讨 CBD 对精神病潜在神经化学机制的影响。
我们采用双盲、随机、安慰剂对照、重复测量、自身交叉设计,研究了单剂量 CBD(600mg)对精神病患者的影响。给药后,13 名患者接受质子磁共振波谱检查,以测量左海马回谷氨酸水平。在给药前 60 分钟(扫描前)和给药后 270 分钟(扫描后)使用阳性和阴性症状量表(PANSS)评估症状严重程度。研究了 CBD 对海马回谷氨酸水平、症状严重程度以及海马回谷氨酸与症状之间相关性的影响。
与安慰剂相比,CBD 治疗组的海马回谷氨酸水平显著升高(=0.035),症状严重程度显著降低(=0.032)。当控制基线 PANSS 评分、治疗(CBD 与安慰剂)和谷氨酸水平与治疗的相互作用时,治疗后总 PANSS 评分与海马回谷氨酸之间也存在显著的负相关(=0.047)。
这些发现可能表明,在精神病患者中观察到的 CBD 治疗后谷氨酸水平升高与症状严重程度降低之间存在关联。此外,这些发现为 CBD 的抗精神病作用的潜在神经化学机制提供了新的见解。